Restoration of coronary flow in myocardial infarction by intravenous chimeric 7E3 antibody without exogenous plasminogen activators: Observations in animals and humans

Herman K. Gold, Harry D. Garabedian, Robert E. Dinsmore, Luis J. Guerrero, Joaquin Cigarroa, Igor F. Palacios, Robert C. Leinbach

Research output: Contribution to journalArticle

143 Citations (Scopus)

Abstract

Background: Coronary thrombus is composed of platelets and fibrin, and during thrombolytic treatment, reflow may be slowed by platelet deposition. It may be possible to initiate coronary reflow without exogenous plasminogen activators by blocking platelet aggregation while fibrin generation is impeded with heparin. Methods and Results: In 14 dogs, left anterior descending coronary artery thrombosis was produced by endothelial trauma and thrombin instillation in the presence of stenosis distally. Reflow was monitored by flow probe during treatment with (1) heparin, (2) heparin and aspirin, and (3) heparin, aspirin, and intravenous 7e3. Eighty percent of dogs treated with the third combination showed stable reflow (≤ 25% of prestenotic flow) in 50 ±9 minutes. In addition, 13 patients were studied during intravenous administration of c7E3 10 minutes before primary angioplasty for acute myocardial infarction and Thrombolysis In myocardial Infarction (TIMI) grade 0 or 1 flow. Pretreatment included heparin and oral aspirin. Flow increased during a 10-minute period by at least one TIMI grade in 11 (85%) of 13 and reached TIMI grade 2 or 3 in 7 (54%) of 13 patients. Average TIMI grade flow increased from 0.31 ± 0.5 to 1.54±0.8 (P

Original languageEnglish (US)
Pages (from-to)1755-1759
Number of pages5
JournalCirculation
Volume95
Issue number7
StatePublished - Apr 1 1997
Externally publishedYes

Fingerprint

Plasminogen Activators
Heparin
Myocardial Infarction
Antibodies
Aspirin
Fibrin
Blood Platelets
Dogs
Coronary Thrombosis
Platelet Aggregation
Angioplasty
Thrombin
Intravenous Administration
Coronary Vessels
Pathologic Constriction
Thrombosis
Wounds and Injuries
Therapeutics

Keywords

  • 7E3
  • myocardial infarction
  • platelet aggregation inhibitors
  • reperfusion

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Gold, H. K., Garabedian, H. D., Dinsmore, R. E., Guerrero, L. J., Cigarroa, J., Palacios, I. F., & Leinbach, R. C. (1997). Restoration of coronary flow in myocardial infarction by intravenous chimeric 7E3 antibody without exogenous plasminogen activators: Observations in animals and humans. Circulation, 95(7), 1755-1759.

Restoration of coronary flow in myocardial infarction by intravenous chimeric 7E3 antibody without exogenous plasminogen activators : Observations in animals and humans. / Gold, Herman K.; Garabedian, Harry D.; Dinsmore, Robert E.; Guerrero, Luis J.; Cigarroa, Joaquin; Palacios, Igor F.; Leinbach, Robert C.

In: Circulation, Vol. 95, No. 7, 01.04.1997, p. 1755-1759.

Research output: Contribution to journalArticle

Gold, Herman K. ; Garabedian, Harry D. ; Dinsmore, Robert E. ; Guerrero, Luis J. ; Cigarroa, Joaquin ; Palacios, Igor F. ; Leinbach, Robert C. / Restoration of coronary flow in myocardial infarction by intravenous chimeric 7E3 antibody without exogenous plasminogen activators : Observations in animals and humans. In: Circulation. 1997 ; Vol. 95, No. 7. pp. 1755-1759.
@article{af751410d2e64c0d8091dcebe8a320cf,
title = "Restoration of coronary flow in myocardial infarction by intravenous chimeric 7E3 antibody without exogenous plasminogen activators: Observations in animals and humans",
abstract = "Background: Coronary thrombus is composed of platelets and fibrin, and during thrombolytic treatment, reflow may be slowed by platelet deposition. It may be possible to initiate coronary reflow without exogenous plasminogen activators by blocking platelet aggregation while fibrin generation is impeded with heparin. Methods and Results: In 14 dogs, left anterior descending coronary artery thrombosis was produced by endothelial trauma and thrombin instillation in the presence of stenosis distally. Reflow was monitored by flow probe during treatment with (1) heparin, (2) heparin and aspirin, and (3) heparin, aspirin, and intravenous 7e3. Eighty percent of dogs treated with the third combination showed stable reflow (≤ 25{\%} of prestenotic flow) in 50 ±9 minutes. In addition, 13 patients were studied during intravenous administration of c7E3 10 minutes before primary angioplasty for acute myocardial infarction and Thrombolysis In myocardial Infarction (TIMI) grade 0 or 1 flow. Pretreatment included heparin and oral aspirin. Flow increased during a 10-minute period by at least one TIMI grade in 11 (85{\%}) of 13 and reached TIMI grade 2 or 3 in 7 (54{\%}) of 13 patients. Average TIMI grade flow increased from 0.31 ± 0.5 to 1.54±0.8 (P",
keywords = "7E3, myocardial infarction, platelet aggregation inhibitors, reperfusion",
author = "Gold, {Herman K.} and Garabedian, {Harry D.} and Dinsmore, {Robert E.} and Guerrero, {Luis J.} and Joaquin Cigarroa and Palacios, {Igor F.} and Leinbach, {Robert C.}",
year = "1997",
month = "4",
day = "1",
language = "English (US)",
volume = "95",
pages = "1755--1759",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Restoration of coronary flow in myocardial infarction by intravenous chimeric 7E3 antibody without exogenous plasminogen activators

T2 - Observations in animals and humans

AU - Gold, Herman K.

AU - Garabedian, Harry D.

AU - Dinsmore, Robert E.

AU - Guerrero, Luis J.

AU - Cigarroa, Joaquin

AU - Palacios, Igor F.

AU - Leinbach, Robert C.

PY - 1997/4/1

Y1 - 1997/4/1

N2 - Background: Coronary thrombus is composed of platelets and fibrin, and during thrombolytic treatment, reflow may be slowed by platelet deposition. It may be possible to initiate coronary reflow without exogenous plasminogen activators by blocking platelet aggregation while fibrin generation is impeded with heparin. Methods and Results: In 14 dogs, left anterior descending coronary artery thrombosis was produced by endothelial trauma and thrombin instillation in the presence of stenosis distally. Reflow was monitored by flow probe during treatment with (1) heparin, (2) heparin and aspirin, and (3) heparin, aspirin, and intravenous 7e3. Eighty percent of dogs treated with the third combination showed stable reflow (≤ 25% of prestenotic flow) in 50 ±9 minutes. In addition, 13 patients were studied during intravenous administration of c7E3 10 minutes before primary angioplasty for acute myocardial infarction and Thrombolysis In myocardial Infarction (TIMI) grade 0 or 1 flow. Pretreatment included heparin and oral aspirin. Flow increased during a 10-minute period by at least one TIMI grade in 11 (85%) of 13 and reached TIMI grade 2 or 3 in 7 (54%) of 13 patients. Average TIMI grade flow increased from 0.31 ± 0.5 to 1.54±0.8 (P

AB - Background: Coronary thrombus is composed of platelets and fibrin, and during thrombolytic treatment, reflow may be slowed by platelet deposition. It may be possible to initiate coronary reflow without exogenous plasminogen activators by blocking platelet aggregation while fibrin generation is impeded with heparin. Methods and Results: In 14 dogs, left anterior descending coronary artery thrombosis was produced by endothelial trauma and thrombin instillation in the presence of stenosis distally. Reflow was monitored by flow probe during treatment with (1) heparin, (2) heparin and aspirin, and (3) heparin, aspirin, and intravenous 7e3. Eighty percent of dogs treated with the third combination showed stable reflow (≤ 25% of prestenotic flow) in 50 ±9 minutes. In addition, 13 patients were studied during intravenous administration of c7E3 10 minutes before primary angioplasty for acute myocardial infarction and Thrombolysis In myocardial Infarction (TIMI) grade 0 or 1 flow. Pretreatment included heparin and oral aspirin. Flow increased during a 10-minute period by at least one TIMI grade in 11 (85%) of 13 and reached TIMI grade 2 or 3 in 7 (54%) of 13 patients. Average TIMI grade flow increased from 0.31 ± 0.5 to 1.54±0.8 (P

KW - 7E3

KW - myocardial infarction

KW - platelet aggregation inhibitors

KW - reperfusion

UR - http://www.scopus.com/inward/record.url?scp=0030998690&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030998690&partnerID=8YFLogxK

M3 - Article

C2 - 9107158

AN - SCOPUS:0030998690

VL - 95

SP - 1755

EP - 1759

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 7

ER -